Weatherford International's rise in ROCE and decrease in capital employed suggest enhanced efficiency in generating returns. The substantial total return over the past three years signals investors' anticipation of more positive future performance.
Weatherford International's high P/S ratio isn't justified given its below-industry projected revenue growth. The company's current price levels and not so promising growth outlook warrant investor caution. Future disappointment is possible if P/S falls to match the growth outlook.
Market Summary 15/8/2023 August kicked off with a noticeable 5% dip in the QQQ. However, a respite was observed, likely due to the$ARK Innovation ETF(ARKK.US)$ETF's continuous downfall in the last nine sessions, leading to a significant 17% drop this month. Such sharp declines are expected after robust growth periods, but it's concerning when they coincide with a trend switch to net lows. Even with today's market uplift, there was a rise in net lows for the Nasdaq an...
ウェザーフォード インターナショナルに関するコメント
August kicked off with a noticeable 5% dip in the QQQ. However, a respite was observed, likely due to the $ARK Innovation ETF(ARKK.US)$ ETF's continuous downfall in the last nine sessions, leading to a significant 17% drop this month. Such sharp declines are expected after robust growth periods, but it's concerning when they coincide with a trend switch to net lows. Even with today's market uplift, there was a rise in net lows for the Nasdaq an...
• $DBVテクノロジーズ(DBVT.US)$ +23.5% (positive topline results from Phase 3 EPITOPE Trial)
• $アルデイラ セラピューティクス(ALDX.US)$ +19.2% (achieves primary endpoint in phase 3 tranquility-2 trial)
• $メディシノバ(MNOV.US)$ +11.9% (top-line results from phase 2 clinical trial of MN-166)
• $トーリッド ホールディングス(CURV.US)$ +11% (In reaction to earnings/guidance)
• $ノババックス(NVAX.US)$ +10.1% (FDA advisory committee recommends EUA for its COVID-19 v...
• $セレス セラピューティクス(MCRB.US)$ : Jefferies Upgrades to Buy from Hold
• $フェラーリ(RACE.US)$ : Kepler Upgrades to Hold from Reduce
Downgrades
• $ダッチ ブロス A(BROS.US)$ : JPMorgan Downgrades to Neutral from Overweight - PT $40
• $キャノピー グロース(CGC.US)$ : BMO Capital Downgrades to Underperform from Market Perform - PT Cdn$2.50 (from Cdn$6)
• $カズー グループ(CZOO.US)$ : Citigroup Downgrades to Neutral from Buy - PT $1.50 (from $9)
• $チャート インダストリーズ(GTLS.US)$ : Barcla...
まだコメントはありません